Glabridina

Otros Nombres

(R)-4-(3,4-Dihydro-8,8-dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-3-yl)-1,3-benzenediol(R)-4-(8,8-Dimethyl-2,3,4,8-tetrahydropyrano[2,3-f]chromen-3-yl)benzene-1,3-diol(R)-4-(8,8-dimethyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromen-3-yl)benzene-1,3-diol(R)-Glabridin1,3-Benzenediol, 4-(3,4-dihydro-8,8-dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-3-yl)-, (R)-1,3-Benzenediol, 4-[(3R)-3,4-dihydro-8,8-dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-3-yl]-4-((R)-8,8-Dimethyl-3,4-dihydro-2H,8H-benzo[1,2-b:4,3-b']dipyran-3-yl)-benzene-1,3-diol4-(3,4-dihydro-8,8-dimethyl-2H,8H-benzo(1,2-b:3,4-b')dipyran-3-yl)-1,3-benzenediol4-[(3R)-3,4-Dihydro-8,8-dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-3-yl]-1,3-benzenediol4-[(3R)-8,8-Dimethyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromen-3-yl]-1,3-benzenediol4-[(3R)-8,8-Diméthyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromén-3-yl]-1,3-benzènediol4-[(3R)-8,8-Dimethyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromen-3-yl]-1,3-benzoldiol4-[(3R)-8,8-Dimethyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromen-3-yl]benzene-1,3-diolGlabridine

Sinopsis

Glabridin: A Comprehensive Reference Article

1. Identity and Chemical Characterization

Botanical Source and Nomenclature

Glabridin is a chemical compound found in the root extract of licorice (Glycyrrhiza glabra). It is a species-specific biomarker from the roots of Glycyrrhiza glabra L. (European licorice, Fabaceae). The licorice plant belongs to the genus Glycyrrhiza (Fabaceae), which includes Glycyrrhiza uralensis F., a species native to China, and Glycyrrhiza glabra L., a species native to southern Europe, India, and parts of Asia. Among the commercially significant licorice species, G. glabra, G. inflata, and G. uralensis are the most widely used, often interchangeably, for different productions.

Chemical Classification and Structure

Glabridin is an isoflavane — a type of isoflavonoid — and belongs to a larger family of plant-derived molecules known as natural phenols. More specifically, glabridin is a prenylated isoflavan, which was first isolated from the roots of Glycyrrhiza glabra by Shibata and Saitoh in 1978. Structural research confirms that glabridin is a prenylated isoflavan, and its systematic IUPAC name is 4-[(3R)-8,8-dimethyl-3,4-dihydro-2H-pyrano[2,3-f]chromen-3-yl]benzene-1,3-diol.

Stereochemical analysis — including circular dichroism, NMR data, and X-ray diffraction data with Bijvoet differences — confirms that glabridin purified from its natural source is found only in a C3 R configuration.

Glabridin is a yellowish-brown powder. It is insoluble in water but soluble in organic solvents such as propylene glycol. This poor water solubility is a significant limitation for its pharmaceutical and clinical applications.

Concentration in the Plant

Glabridin is a major constituent of licorice root (Glycyrrhiza glabra), constituting approximately 0.1% to 0.4% of the root dry weight. The principal isoflavane of G. glabra, it ranges between 0.08% and 0.35% of root dry weight, and accounts for approximately 11% of the plant's total flavonoid content. Glabridin is the main prenylated isoflavonoid of licorice and is considered a species-specific marker compound.

Related Compounds

Along with glabridin, related compounds in G. glabra include licoricidin (also known as licorisoflavan B), hispaglabridin A, glyasperin C, glyasperin D, and 3′-hydroxy-4′-O-methylglabridin. Glabridin, licochalcone A, glycyrrhizin, and 18β-glycyrrhetinic acid are among the notable phytochemicals isolated from licorice and have been extensively explored for biological and pharmacological activities.

2. Traditional and Historical Use

Global Traditional Use of Licorice Root

Ethnomedicinal uses of licorice have frequently been described in the world's renowned medical systems, including Ayurveda, Unani, Chinese, Korean, Japanese, African, and European traditional medical systems. Licorice extract has been used for centuries as a food additive (sweetener), in cosmetics, and in traditional medicine.

In traditional Chinese medicine (TCM), Glycyrrhiza glabra is considered an "essential herbal medication." According to TCM tradition, "nine out of ten formulae contain licorice," and licorice is regarded as one of the most effective herbal medicines for reducing the toxicity and increasing the efficacy of other herbal medicines when used together.

The roots and rhizomes of licorice plants (genus Glycyrrhiza L.) are commercially employed, after processing, in confectionery production or as sweetening and flavouring agents in the food, tobacco, and beer industries.

Traditional Medicinal Preparations

Traditional uses of licorice root extracts have historically included treating throat infections, tuberculosis, respiratory and liver diseases, and as an antibacterial and anti-inflammatory agent. Topical anti-inflammatory activity has been noted, and licorice extract is one of the most frequently used botanical extracts in cosmetics.

It is important to note that in traditional use, licorice root was administered as whole-root preparations — decoctions, powders, pastes, and herbal blends — not as isolated glabridin. Both glabridin and standardized licorice extracts have had significant impact on food, dietary supplement, and cosmetic markets, as evidenced by the number of patents and scientific articles since 1976, when glabridin was first described. Glabridin as an isolated or highly concentrated compound is exclusively a modern characterization.

3. Key Constituents, Active Compounds, and Mechanisms of Action

Structural Basis of Activity

The ring-B hydroxyl groups of glabridin provide strong sinks for free radical electrons, underlying its antioxidant activity. Structure-activity relationship research indicates that the two phenol hydroxyl groups (C2' and C4') in the B ring are important for inactivating cytochrome P450 enzymes (CYPs) and triggering pharmacological activity.

Anti-Inflammatory Mechanisms

In different cell lines, it has been observed that glabridin can inhibit the inflammatory response by inhibiting the NF-κB signaling pathway and the expression of cytokines and chemokines. Specifically, by inhibiting NF-κB/Rel DNA binding activity and NF-κB/Rel-dependent reporter gene activity, glabridin (at 0.3–10 μmol/L) inhibited the expression of iNOS and NO production in LPS-induced RAW 264.7 cells.

In LPS-stimulated macrophage models, glabridin and its synthetic derivatives significantly and dose-dependently suppressed the production of nitric oxide (NO) and prostaglandin E2 (PGE2), decreased the levels of iNOS and COX-2, and reduced pro-inflammatory cytokines IL-1β, IL-6, and TNF-α; these compounds inhibited nuclear translocation of NF-κB by blocking phosphorylation of IκBα and distinctively inhibited phosphorylation of ERK, JNK, and p38 MAPKs.

Virtual docking studies find that glabridin may interact with PTGS2 (COX-2) protein; this was verified by a surface plasmon resonance (SPR) assay, with a dissociation rate constant (Kd) of 44.5 μM indicating strong binding affinity.

Antioxidant Mechanisms

Although glabridin was first isolated while searching for an antimicrobial agent in licorice root by bioassay-directed fractionation, most early research focused on its effects on LDL oxidation; Vaya et al. reported that glabridin is the most abundant and potent antioxidant constituent toward LDL oxidation among seven constituents isolated from licorice root. That work showed that glabridin significantly suppressed AAPH-induced LDL oxidation in a cell-free system, and also showed a dose-dependent inhibitory effect on AAPH-induced formation of cholesteryl linoleate hydroperoxide in LDL particles.

Tyrosinase Inhibition (Skin-Lightening Mechanism)

Glabridin inhibited tyrosinase activity of melanoma cells at concentrations of 1.0 μg/mL without affecting DNA synthesis; it was also shown to inhibit UVB-induced pigmentation and inflammation on guinea pig skins at 0.5% w/v concentration. Yokota and colleagues concluded that the two hydroxyl groups at the 2 and 4 positions of glabridin are essential for tyrosinase inhibitory activity.

PPARγ Activation and Metabolic Regulation

Glabridin was shown to bind to and activate PPARγ (peroxisome proliferator-activated receptor gamma), and also to activate PPARγ-regulated gene expression in human hepatoma cells similarly to known PPARγ ligands; the expression was blocked by a PPARγ-specific antagonist. It is generally believed that glabridin regulates blood lipids and blood glucose metabolism partly by activating the expression of PPARγ and C/EBPα.

AMPK Activation

Glabridin has demonstrated anti-obesity effects through activation of AMP-activated protein kinase (AMPK), mitochondrial activity, and fatty acid oxidation. Glabridin may activate AMPK expression and thereby enhance the oxidation of fatty acids by downregulating genes involved in lipid metabolism, such as SREBP-1c, FAS, ACC, and SCD-1, and by increasing mitochondrial function.

Multiple Signaling Pathways

Many signaling pathways have been implicated in the regulatory activities of glabridin, including NF-κB, MAPK, Wnt/β-catenin, ERα/SRC-1, PI3K/AKT, and AMPK.

Phytoestrogenic Activity

Glabridin has been widely considered to be a phytoestrogen, though there is disagreement among researchers on whether glabridin has estrogenic effects. It acts on estrogen receptor alpha (ERα) and the SRC-1 co-activator pathway, but the net effect — agonist or antagonist — appears to be tissue- and context-dependent, and this area remains unresolved.

Antiplatelet Activity

Glabridin effectively inhibits platelet activation, and might become a therapeutic agent for thromboembolic disorders.

4. Scientific Evidence by Area of Use

4.1 Skin Hyperpigmentation and Dermatology

This is the area with the most substantial, and most directly applicable, evidence for glabridin itself. Glabridin's skin-lightening effect operates primarily through tyrosinase inhibition.

Preclinical evidence: Among the compounds identified in G. glabra ethanol extract — including liquiritin, isoliquiritigenin, and glabridin — glabridin demonstrated the most potent melanin-inhibitory activity in both in vivo and in vitro models.

Human/clinical evidence: In a clinical trial, 2.5% G. glabra cream was applied to 100 females for four weeks. The study concluded that treatment significantly improved symptoms of melasma compared to the placebo group without any side effects. A single-center, double-blind clinical study of 18 subjects comparing the efficacy of a hydroquinone-free formula containing glabridin found significant reductions in ultraviolet-induced hyperpigmentation when compared to both the negative control and 4% hydroquinone cream.

Evidence strength: The clinical evidence for topical glabridin-containing formulations in hyperpigmentation/melasma is preliminary but directionally positive. Most studies are small, of short duration, and test glabridin as part of multi-ingredient extracts or formulations rather than as an isolated pure compound. Standardization of glabridin content across tested preparations varies widely.

Glabridin is used as an ingredient in cosmetics and is listed in the International Nomenclature of Cosmetic Ingredients (INCI).

4.2 Anti-Inflammatory Effects

Preclinical/mechanistic evidence: A robust body of cell-based and animal study evidence demonstrates that glabridin suppresses multiple inflammatory mediators. Glabridin (at 0.5–20 μmol/L) inhibited the inflammatory response in LPS-induced RAW 264.7 macrophages by inhibiting the expression of IL-1β, TNF-α, IL-6, IL-8, MCP-1, and NO. At 5–20 μmol/L, glabridin also inhibited LPS- and zymosan-induced phenotypic maturation of dendritic cells by attenuating production of IL-12, IL-1β, TNF-α, and IFN-α/β, and impairing induction of allogenic T cell activation.

In a rodent model of colitis, mRNA levels of TNF-α and IL-6 in the colons of DSS-treated mice were significantly increased; these increases were attenuated with glabridin administration (50 mg/kg) by 76% and 80%, respectively.

In tests including carrageenan-induced paw edema, air pouch, acetic-acid-induced writhing, formalin, and capsaicin tests in rats and mice (n = 8) administered glabridin for 3 days at three doses (10, 20, and 40 mg/kg), glabridin inhibited cytokine production and showed an anti-nociceptive response via the activation of BKCa channels and downregulation of NO levels and partially transient receptor potential vanilloid-1 pathways.

Human/clinical evidence: There are no large-scale, adequately powered human clinical trials specifically isolating the anti-inflammatory effects of pure glabridin at this time. Cell experiments and animal experiments have confirmed that glabridin has a good anti-inflammatory effect and is expected to be used for the treatment of many diseases by inhibiting the NF-κB signaling pathway and the expression of various cytokines and chemokines.

Evidence strength: In vitro and animal evidence is strong and mechanistically consistent. Human clinical evidence is lacking for pure glabridin as an anti-inflammatory agent.

4.3 Cardiovascular Health and Lipid Metabolism

Preclinical/mechanistic evidence: Early research suggested the possibility that dietary supplementation of glabridin or licorice extract might protect plasma LDL from oxidation and suppress the development of atherosclerosis. Studies have reported that glabridin can protect blood vessels by inhibiting LDL oxidation.

Clinical evidence: Clinical studies of licorice flavonoid oil (LFO), a standardized preparation containing glabridin, have examined cardiovascular parameters. Plasma glabridin levels showed a linear dose relationship and reached steady state within two weeks of daily dosing. At two weeks, there were significant changes in platelet count for the highest dose (1200 mg/day), but the changes were not considered clinically significant; overall, there were no clinically relevant changes in hematological or biological parameters.

Evidence strength: Preliminary. Most cardiovascular evidence derives from cell-culture and animal studies. Human studies are small, short-term, and primarily pharmacokinetic rather than outcome-focused.

4.4 Obesity and Metabolic Syndrome

This area has generated the most active clinical-stage drug development work, particularly through the synthetic glabridin derivative vutiglabridin (HSG4112).

Preclinical evidence: In high-fat diet (HFD)-induced obese male C57BL/6J mice, synthetic compounds derived from a structure–activity relationship (SAR) study of glabridin — a natural compound known to reduce body weight and influence energy homeostasis — were systematically evaluated for weight-loss effect. In preclinical studies using diet-induced obese mice, vutiglabridin (a synthetic glabridin derivative) improved lipid profiles by lowering serum triglyceride levels and normalizing HDL, LDL, and total cholesterol levels.

Clinical evidence (vutiglabridin / HSG4112 — synthetic derivative): Vutiglabridin, a synthetic glabridin derivative, is under clinical development for the treatment of obesity. Single oral doses up to 720 mg were safe and well-tolerated, and showed a biphasic distribution profile in a previous Phase I study. The plasma concentration of vutiglabridin reached higher peak levels but was associated with lower systemic exposure in obese subjects than in healthy females, although overall pharmacokinetic profiles were comparable; short-term exploratory pharmacodynamic assessments suggested potential metabolic benefits, supporting the need for further evaluation in long-term clinical trials.

Based on current experimental conclusions, especially clinical trial results, glabridin is considered most likely to have utility in reducing blood lipids and blood glucose in obese or diabetic patients.

Evidence strength: For natural glabridin itself, evidence of anti-obesity efficacy in humans is preliminary and largely indirect. The clinical development program for vutiglabridin is more advanced but involves a structurally modified synthetic analog, not glabridin itself.

4.5 Neuroprotection

Preclinical evidence: Glabridin has been associated with neuroprotective properties. Inflammation has been involved in the pathological development of many neurodegeneration diseases, such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Glabridin has demonstrated anti-neuroinflammatory effects in microglial cell models, and has been studied in various neuropathological animal contexts.

Bioavailability challenge: Despite interesting neuroprotective activities, the bioavailability of glabridin in the brain could be compromised due to its interaction with P-glycoprotein (P-gp), which is expressed notably in capillary endothelial cells.

Human/clinical evidence: There are currently no published human clinical trials specifically examining glabridin's neuroprotective efficacy as a primary endpoint. At present, these studies are mostly based on cell and animal experiments, and more clinical studies are necessary in the future.

Evidence strength: Preclinical only. No clinical translation has been established.

4.6 Bone Health and Anti-Osteoporosis

Preclinical evidence: Glabridin, which exerts hypoglycemic effects and possesses antioxidant properties, may have beneficial effects in the treatment of diabetes-related osteoporosis. Diabetes significantly decreased rats' tibia length, bone thickness, epiphyseal plate length, and collagen deposition compared to controls; treatment with glabridin for 8 weeks significantly reversed these effects. Glabridin alleviated oxidative stress-induced bone loss and osteoblast cell apoptosis by modulating the expression of the Akt/NF-κB and Akt/GSK-3β pathways.

Evidence strength: Preclinical (cell and rodent) evidence only. No human clinical trials specifically evaluating glabridin for osteoporosis have been published.

4.7 Anticancer Activity

Preclinical evidence: Studies have shown that glabridin exhibits substantial antitumor activity by modulating the proliferation, apoptosis, metastasis, and invasion of cancer cells through targeting of various signaling pathways, indicating its potential as a therapeutic agent for malignant tumors. Mechanisms studied in cell lines include induction of cellular autophagy, cell cycle arrest, inhibition of tumor angiogenesis, and enhancement of chemotherapy drug sensitivity.

Human/clinical evidence: None established. All published anticancer data for glabridin originate from cell-culture and animal experiments.

Evidence strength: Preliminary preclinical interest only. Clinical translation is entirely absent.

4.8 Antimicrobial Activity

Glabridin has been associated with antibacterial properties. The pharmacological effects of glabridin include the prevention of Staphylococcus, Candida, and other bacterial infections. Activity against Prevotella intermedia, a periodontal pathogen, has also been explored in vitro using licorice extracts containing glabridin.

Evidence strength: In vitro and limited preclinical data. No clinical trials have specifically examined glabridin's antimicrobial effects in human subjects.

5. Body Systems and Health Areas of Association

Skin/Integumentary system: Tyrosinase inhibition, hyperpigmentation, melasma, UV-induced erythema, anti-inflammatory topical action — the best-evidenced area at a clinical level.
Immune/Inflammatory system: Suppression of macrophage, dendritic cell, and keratinocyte inflammatory signaling (NF-κB, MAPK, COX-2, cytokine expression).
Cardiovascular system: Anti-atherosclerotic activity via LDL oxidation inhibition, antiplatelet effects, protection of paraoxonase 1.
Metabolic system (adipose, glucose, lipid): AMPK activation, PPARγ modulation, energy expenditure, insulin sensitivity — active preclinical area with nascent clinical programs via synthetic derivatives.
Nervous system: Anti-neuroinflammatory, potential protection against neurodegenerative disease models — preclinical only.
Skeletal system: Anti-osteoporotic activity in diabetic and oxidative stress models — preclinical only.
Oncology: Broad preclinical anticancer data across multiple cancer cell lines — no clinical evidence.
Gastrointestinal system: Glabridin is a key constituent in DGL (deglycyrrhizinated licorice) preparations studied for GI mucosal health, though most GI evidence pertains to the mixed-flavonoid extract, not to isolated glabridin.

6. Dosage Forms and Reported Doses

Natural Source Concentration

The content of glabridin in licorice root is approximately 0.2%. Extraction methods include the use of ethanol/water (30:70, v/v) as a solvent under optimized conditions of 60 minutes dipping time at 50°C.

Commercial Supplement Preparations

Glabridin is not typically sold as an isolated pure compound for supplementation, but rather as part of standardized extracts or specific commercial formulations. The two most clinically studied are:

Licorice Flavonoid Oil (LFO) / Glavonoid® (Kaneka, Japan): Glavonoid® has been the most clinically tested licorice flavonoid extract; it was granted Generally Recognized As Safe (GRAS) status by the FDA in 2008 and Novel Food Status by the European Commission in 2011. It is comprised of an ethanol extract of G. glabra containing 3% w/w glabridin, and the formulation is a mixture of 30% extract with 70% medium chain triglycerides (MCTs) (C8:C10 = 99:1); this licorice flavonoid oil containing MCTs has higher dissolved flavonoid content than powdered licorice ethanolic extract.
GutGard® (Natural Remedies): GutGard is a flavonoid-rich DGL extract standardized to contain greater than 3.5% glabridin and greater than 10% total flavonoids, with glycyrrhizin no more than 3% w/w; this is the extract used in most recent clinical trials, with a typical dose of 75 mg twice daily.

Doses Reported in Clinical Studies

In healthy volunteers given oral licorice flavonoid oil (GLFO) at 300–1,200 mg/day, pharmacokinetic parameters showed Tmax of 3.2–3.6 h, T½ of 8.3–13.9 h, Cl/F of 308–367 L/h, Cmax of 1.12–2.65 ng/mL, and AUC0–24h of 10.08–31.55 ng·h/mL.

The manufacturer-recommended dose for Glavonoid® is 300 mg/day; however, in clinical studies, potential benefits were more apparent at higher doses. There is currently no established clinically effective dose for any indication.

For the synthetic glabridin derivative vutiglabridin, single oral doses up to 720 mg were safe and well-tolerated in a Phase I study.

For topical applications, glabridin has been studied at 0.5% w/v in formulations for inhibiting UVB-induced pigmentation and inflammation on skin.

7. Pharmacokinetics and Bioavailability

In animal studies, glabridin peaks at 87 nmol/L one hour post-administration, with a half-life of 8.2 hours and AUCinf of 0.825 μM·h. Glabridin has an oral bioavailability of 6.63% and a first-pass effect in the liver of 62.12%.

Poor water solubility and low bioavailability have greatly limited the clinical applications of glabridin. To address this, formulations including microneedles, liposomes, and smartPearls preparations are available for glabridin to enhance bioavailability.

Multiple UDP-glucuronosyltransferases (UGTs), including UGT1A1, 1A3, 1A9, 2B7, 2B15, and intestinal UGT1A8 and 1A10, are able to carry out glabridin glucuronidation. Among these, UGT1A8 displayed the highest activity, with a Clint value more than 5-fold higher than other forms.

Despite neuroprotective activities, the bioavailability of glabridin in the brain could be compromised due to its interaction with P-glycoprotein (P-gp), which is expressed notably in capillary endothelial cells.

Vutiglabridin, the synthetic derivative of glabridin, was developed specifically to increase metabolic stability and oral bioavailability for anti-obesity treatment.

8. Safety Considerations and Drug Interactions

General Safety Profile

Animal studies demonstrate that licorice flavonoid oil is highly safe; in an 8-week study involving LFO intervention in obese mice, there were no significant differences in liver, kidney, and spleen weights between treated and control groups, suggesting that glabridin is non-toxic at tested doses.

In human pharmacokinetic studies, at two weeks there were significant changes in platelet count for the highest dose (1,200 mg/day), but the changes were not considered clinically significant; overall there were no clinically relevant changes in hematological or biological parameters, and clinical trials examining metabolic effects of licorice flavonoid oil reported good tolerability and a lack of serious adverse events.

Glabridin may be degraded at room temperature, and it should be kept under dry, dark, and low-oxygen conditions.

Distinction from Glycyrrhizin Toxicity

A critical point in evaluating glabridin safety is to distinguish it from glycyrrhizin, the triterpenoid saponin in licorice that is responsible for the well-documented adverse effect of pseudoaldosteronism (sodium retention, hypertension, hypokalemia) associated with excess licorice consumption. Traditional licorice preparations contained glycyrrhizin and saponins; modern DGL (deglycyrrhizinated licorice) intentionally removes glycyrrhizin to avoid pseudoaldosteronism while preserving flavonoid-driven effects. Glabridin is a flavonoid — chemically and pharmacologically distinct from glycyrrhizin — and the mineralocorticoid side-effects attributed to licorice are not attributable to glabridin.

Cytochrome P450 Interactions

This is the most thoroughly documented area of glabridin safety concern, as it may alter the metabolism of co-administered drugs:

CYP3A4: An earlier study demonstrated that glabridin was a mechanism-based inhibitor of CYP3A4, which was thought likely to result in interactions with dietary chemicals and drugs, and further induce corresponding toxic effects.
CYP2E1: Glabridin has been identified as a potential inhibitor of CYP2E1; in human liver microsomes in vitro, glabridin exhibits inhibitory activity against CYP2E1 with an IC50 of 6.2 μM, greater than that of fisetin, epicatechin, nobiletin, and chrysin.
CYP2C9: The activity of CYP2C9 can be competitively blocked by glabridin.
CYP2B6: Interaction between glabridin and CYP2B6 does not result in modification of the heme moiety; HPLC analysis indicates that incubations with glabridin and NADPH do not lead to destruction of the heme moiety.

More investigation of glabridin's interaction with CYPs is still needed due to its wide application as a supplementary agent in foods and medicines. Particularly, cases in which irreversible inactivation of target enzymes may occur should be monitored.

An IC50 value of the extract that is lower than that of the pure compound indicates that care should be taken when administering the extract with other CYP450-interacting compounds, particularly those with a low therapeutic index.

Estrogenic Activity: Unresolved Question

There is disagreement among researchers on whether glabridin has estrogenic effects. Glabridin has been studied as a phytoestrogen through ERα and the SRC-1 co-activator pathway, but published data show both agonist and antagonist effects depending on the cell type, concentration, and hormonal context. Until this is resolved, individuals with hormone-sensitive conditions should be aware of this uncertainty.

P-Glycoprotein Inhibition

Glabridin has been considered an inhibitor of P-glycoprotein (P-gp), a key efflux transporter expressed in the intestinal epithelium, blood–brain barrier, and many other tissues. P-gp inhibition can alter the absorption and distribution of co-administered drugs that are P-gp substrates.

Pharmacokinetic Drug Interactions

Pharmacokinetic research shows that glabridin is easily absorbed by the human body, and the inhibitory effects of glabridin on some metabolic enzymes can improve the pharmacokinetic characteristics of other medicines. Glabridin has an inhibitory effect on a variety of human metabolic enzymes, which makes it potentially useful to improve the pharmacokinetic characteristics of other medicines — but also raises the possibility of unintended interactions.

9. Current Status and Future Directions

Glabridin has been associated with a wide range of biological properties including antioxidant, anti-inflammatory, anti-atherogenic, regulation of energy metabolism, estrogenic, neuroprotective, anti-osteoporotic, and skin-whitening activities. However, while glabridin has a wide range of pharmacological properties, current studies are mostly based on cell and animal experiments, and more clinical studies are necessary in the future.

Poor water solubility and low bioavailability have greatly limited the clinical applications of glabridin. Research into nanoparticle delivery systems, cyclodextrin inclusion complexes, liposomal formulations, and structural analogs such as vutiglabridin are active areas aimed at overcoming these limitations.

Vutiglabridin, a synthetic derivative of glabridin, has been developed to increase metabolic stability and oral bioavailability for anti-obesity treatment; clinical data on vutiglabridin remain limited for healthy females and obese individuals, highlighting the need for further pharmacokinetic and safety evaluations.

In summary, glabridin's most evidence-supported clinical application to date is topical use for hyperpigmentation. Its other proposed benefits — anti-inflammatory, anti-obesity, neuroprotective, anti-osteoporotic, and anticancer — are primarily supported by preclinical data, and large-scale, well-controlled human trials are largely absent.

References

Condiciones de Salud

Condiciones de salud que Glabridina puede ayudar a apoyar.

Ayudas Atléticas y para el EjercicioCientífico
Glabridin is the principal active compound of licorice root (Glycyrrhiza glabra), a potent tyrosinase inhibitor that reduces melanin synthesis without causing skin irritation and has anti-inflammatory and photoprotective effects relevant to periorbital hyperpigmentation. A systematic review in PMC (PMC5843359) documents multiple RCTs confirming licorice extract components' clinical efficacy in treating melasma and UV-induced pigmentation, conditions mechanistically related to dark circles.
Tratamiento del Cáncer (reducción de efectos secundarios)Científico
Glabridin, the principal isoflavan of licorice root, inhibits tyrosinase and UVB-induced pigmentation, with in vitro potency reportedly 16 times greater than hydroquinone. A single-center, double-blind clinical study of 18 subjects demonstrated superior lightening of UV-induced hyperpigmentation compared to 4% hydroquinone cream.
Pérdida AuditivaCientífico
Glabridin, a principal isoflavane of licorice root, inhibits cyclooxygenase and NF-κB-driven inflammation and reduces skin redness. It is cited in peer-reviewed dermatology literature as a key licorice compound that calms skin and reduces rosacea-related redness, alongside glycyrrhizin. Present in clinically studied licorice-based rosacea formulations.
Sarpullido por pañalCientífico
Glabridin is a primary isoflavane from licorice root (Glycyrrhiza glabra) with documented antiviral activity including against SARS-CoV-2 and influenza. It inhibits viral protease and replication machinery and has anti-inflammatory immunomodulatory properties relevant to viral immune response.

Sistemas Corporales

Sistemas corporales que Glabridina puede ayudar a apoyar.

No hay sistemas corporales disponibles.